What Is the Definition of Acute Leukemia of Ambiguous Lineage?
In the 2008 World Health Organization (WHO) classification, 1 acute leukemias of ambiguous lineage were defined as leukemias that show no clear evidence of differentiation along a single lineage. The recognition of acute leukemia of ambiguous lineage requires extensive multiparametric flow cytometry (FCM) immunophenotyping disclosing the specific features of these diseases ❚Figure 1❚. In extremely rare cases of acute undifferentiated leukemia (AUL), although markers of all lineages have been investigated, no significant expression is detected on blast cells except for CD34 and/or HLA-DR (present in most of these cases). A second, slightly more frequent occurrence is that of blast cells labeling with several monoclonal antibodies, recognizing antigens normally expressed on different lineages. Formerly called biphenotypic acute leukemias (BALs), these neoplasms have been renamed mixed-phenotype acute leukemia (MPAL). On the basis of associated cytogenetic anomalies, MPAL can be subdivided according to the presence of the Philadelphia chromosome into subgroups: t(9;22)/BCR-ABL1, t(v;11q23)/MLL, or not otherwise specified. All other unusual immunophenotypes, including early natural killer (NK) leukemias, constitute the remainder of leukemias of ambiguous origin.
Introduction to MPAL
The morphologic features of the blasts in most cases of MPAL are mostly uninformative, and therefore the diagnosis of MPAL relies exclusively on immunophenotypic features. MPAL cells appear most often as morphologically undifferentiated, but sometimes the neoplastic cells may display more lymphoblastic or myeloblastic cytology. In some cases, two types of blasts with a distinctive size and morphology point to the different, extremely rare occurrence of a bilineal or biclonal leukemia. These neoplasms can also be recognized by FCM analysis as two cell subsets with different immunophenotypes.
MPAL can be identified using the recommended panel of the European LeukemiaNet 2 or other comprehensive combinations. 3 Importantly, several markers specific for the myelo/monocytic lineage as well as for the B-and T-lymphoid lineages must be tested, excluding a restrictive strategy of quick orientation followed by selected lineage-specific markers. Of note, as detailed below, at least two key cytoplasmic (c) markers must be investigated: myeloperoxidase (MPO) for myeloid lineage and cCD3 for T lineage. Recommendations were first published by the European Group for the Immunological Characterization of Leukemias (EGIL), 4 with a scoring system identifying BAL as cases with more than two immunophenotypic points in more than one lineage. This proposal relied on 26 antibodies to perform a proper score, yet published reports seldom applied such extensive panels.
In the 2008 WHO classification, 1 the name of these leukemias and their immunophenotypic definition (as above) were changed. MPO stands as the most robust marker that will identify myeloid engagement. Recent publications have redefined the threshold for MPO positivity, 5, 6 and yet most MPAL cases with a myeloid component will express MPO broadly in most blasts. An alternative, for MPAL with a strong monocytic differentiation, is represented by (very rare) cases in which blasts will be positive for nonspecific esterase and/or express at least two of the following antigens: CD14, CD11c, CD36, CD64, or cytoplasmic lysozyme. Determination of the engagement of blast cells in the B-lymphoid lineage will rely on the expression of surface CD19. If the latter is bright, demonstration of expression of one other B-lineage-associated marker (eg, cCD79a, surface or cCD22, or CD10) will be required. If CD19 expression is weak, however, at least two other B-lineage markers need to be expressed by the blasts. Assessment of T-lineage engagement relies on the demonstration of cCD3 expression as mentioned above. Of note, the fluorochrome used for this determination should yield strong fluorescence, for instance, phycoerythrin or allophycocyanin. The immunophenotypic strategy to explore these cells involves the use of two monoclonal antibodies directed to CD3 (usually anti-e chain) conjugated to different fluorochromes. Cells are first incubated without manipulation, ideally using whole bone marrow (BM). After incubation, permeabilizing reagents will allow both lysis of erythrocytes and intracytoplasmic labeling with the second anti-CD3 antibody. Analysis by FCM will then identify normal residual T lymphocytes as costained with both antibodies, while T-lineage blast cells lacking surface CD3 will be stained with the second anti-CD3 only.
What Possible Combinations of MPAL Occur and What Are Their Frequencies?
All possible combinations of MPAL can be observed, including B/myeloid, T/myeloid, B/T, or even rare B/T/ myeloid. In a series of 100 cases of MPAL published by the EGIL, 7 B/myeloid cases were most frequent, representing 59% of all MPAL cases. The frequencies of T/myeloid, B/T, or B/T/myeloid were 35%, 4%, and 2%, respectively. The blast cells in MPAL show a specific gene expression pattern, as illustrated by a microarray study of acute leukemias performed at St Jude Children's Research Hospital, where 35 childhood MPAL cases segregated in a specific cluster between B-acute lymphoblastic leukemia (B-ALL), T-acute lymphoblastic leukemia (T-ALL), and acute myeloid leukemia (AML). 8 
How Are Patients With MPAL Managed Clinically?
The clinical management of MPAL cases is problematic. Often, an initial course of corticosteroids is attempted, followed by an acute lymphoblastic leukemia (ALL)-like approach. In the absence of response to corticosteroids, most clinicians will switch to an AML-like approach with alkylating agents. However, patients who fared well in the literature were clearly those who could benefit from allogeneic stem cell transplantation.
It is important to identify MPAL cases and not misdiagnose these tumors as ALL or AML by using immunophenotypic panels that are not sufficiently comprehensive. Indeed, some refractory cases of acute leukemia, with poor response to therapy, may represent undetected cases of MPAL that were incorrectly assigned to a single lineage. Using an FCM intracytoplasmic orientation panel combining MPO, cCD3, and CD19 (possibly with cCD79a, cCD22, or CD10) could be a good approach to detect such cases early in the process of immunophenotyping a neoplasm. It is important to point out that immunohistochemistry (IHC) on BM biopsy sections also can be useful to confirm B, T, or myeloid differentiation by using antibodies specific for PAX5, CD3, and MPO and/or lysozyme, respectively. Immunohistochemical analysis may be of great help in cases with two or more different populations with specific distributions in BM or other tissue biopsy specimens since it allows direct visualization of cell location.
Discussion of Workshop Cases
There were 32 cases included in this workshop session. Several cases submitted initially to this session did not completely meet the criteria for MPAL and were moved to other sessions, although the moving in some cases was debated by members of the review panel, revealing the need for more robust criteria and greater consensus on definitions. The workshop cases are discussed in the subtypes to which they were allocated. The summary of these cases (below) illustrates the heterogeneity of MPAL presentation. The following discussion also describes the characteristics of MPAL cases, technical issues involved in MPAL diagnosis, and groups of cases that can be linked by some common characteristics or diagnostic issues. 4, 7, 11 In the case series collected for this workshop, the highly hyperdiploid and/or near-tetraploid karyotype was also common (five [16%] of 32 cases: three B/myeloid, one T/myeloid, and one B/T).
Typical Examples of MPAL

MPAL B/Myeloid
One of the near-tetraploid cases (case 285) carried also the t(12;17)(p13;q11.2) involving the ZNF384/CIZ (chromosome 12p13) and TAF15 (chromosome 17q11.2) genes. The t(12;17)(p13;q11) has been described as a rare but recurrent abnormality, predominantly observed in B-ALL cases that usually have an early pre-B immunophenotype and showing aberrant expression of the myeloid antigens CD13 and/ or CD33. The t(12;17) is less common in AML, and reported cases often showed aberrant expression of CD19. [12] [13] [14] [15] [16] In a recent case report, a pro-B/B-I ALL, which switched to an AML at relapse, was described. 17 Case 285 is the first case with this translocation in which the WHO criteria for MPAL are fulfilled. Another chromosomal abnormality hitherto not described in MPAL, inv(3)(q21q26.2), was detected in case 283. Inv(3)(q21q26.2) or t(3;3)(q21;q26.2) displays an inversion or homologous reciprocal translocation that leads to juxtaposition of the ecotropic viral integration site 1 (EVI1) gene with the ribophorin 1 (RPN1) gene. AML cases carrying this abnormality are classified as one of the categories of AML with recurrent cytogenetic abnormalities in the WHO classification and most commonly have a myeloid or myelomonocytic immunophenotype and poor prognosis. 18, 19 An MPAL phenotype has not been reported previously in a leukemia with inv(3) or t(3;3).
MPAL T/Myeloid
The characteristics of MPAL cases with T and myeloid lineage markers are illustrated in ❚Image 3❚, ❚Image 4❚, and ❚Table 2❚. Most T/myeloid MPALs were characterized by two populations of blasts: one with a T-precursor immunophenotype (usually coexpressing some myeloid markers but negative for MPO) and the other fulfilling MPAL criteria. In two cases (case 139 and 200), the myeloid lineage showed a monocytic differentiation pattern. In two patients (cases 200 and 402), different immunophenotypes were observed in a lymph node biopsy specimen and the BM. In case 200, BM showed an immunophenotype suggestive of AML with monocytic differentiation, but in the lymph node two aberrant populations were detected: one with cCD3 positivity and one with a myelomonocytic immunophenotype. Cytogenetic analysis also showed two different clonal populations,
© American Society for Clinical Pathology one with 46,XY,der(12)t(11;12)(q21;p11.2) and the other with 45,XY,dic(12;18)(p11.2;p11.2). In case 402, a lymph node biopsy specimen showed a T-precursor immunophenotype, whereas in the BM, a population of blasts fulfilling the criteria of MPAL was detected.
MPAL B/T
MPAL cases that express both B-and T-lineage markers are rare (<5% of MPALs). 7 Three examples (cases 312, 359, and 390) were submitted to the workshop ❚Table 3❚ and ❚Image 5❚. In two cases, a population of blasts was detected that coexpressed CD19 (strong) and cCD3. B-cell lineage was supported by CD22 expression in one case and CD79a in the other cases. CD7 was expressed in one of the cases, and no other T-cell-associated markers were seen in the other. One of these cases had a normal karyotype, and one was hyperdiploid. The third MPAL B/T case had trisomy 11 and two populations of blasts: one with an immunophenotype of B-precursor ALL (EGIL B-II) and one of T-ALL with early T-cell precursor immunophenotype (EGIL T-I). 20 
MPAL B/T/Myeloid
Case 268 was the only case of acute leukemia that expressed markers of all three lineages fulfilling criteria for B/T/myeloid MPAL. The patient was a 58-year-old man with two separate leukemic cell populations. One population corresponded to an AML and was positive for CD7, CD4 (dim), CD11b, CD13, CD33, CD34, CD117, MPO, and HLA-DR, and the other population corresponded to MPAL with a B/T immunophenotype positive for TdT, CD19, CD20, CD10, cCD79a, CD22, PAX5, CD33 (dim), cCD3, and CD5 (dim) and negative for MPO ❚Image 6❚ and ❚Image 7❚. Conventional cytogenetics showed a normal karyotype, and BCR-ABL1 was negative. Another case fulfilling criteria for T/myeloid MPAL and also showing weak CD19 expression was case 356 ( Table 2 ). The patient was a 14-year-old girl in whom both a lymph node biopsy specimen and a BM showed blasts positive for cCD3 and MPO with weak expression of CD19 and cCD79a. However, other B-cell markers were not found and the criteria for B-lineage differentiation were not fulfilled.
MLL Rearrangement and Immunophenotype Switch
Cases 180, 256, 370, and 392 were examples of MPAL associated with MLL rearrangement ❚Table 4❚. MPAL with MLL rearrangement is considered a separate entity in the WHO classification, 21 with a frequency of approximately 10% of adult and 12% to 18% of pediatric MPAL cases. 7 Most cases of MPAL with MLL rearrangement are B/ myeloid. Case 256 illustrated a rare occurrence of a T/ myeloid MPAL (Table 4 ). The other three cases demonstrated an immunophenotype switch, previously reported in MLL rearranged leukemias. [22] [23] [24] [25] [26] [27] MLL rearrangement juxtaposes the amino-terminus of the histone methyltransferase MLL with a variety of different fusion partners. To date, more than 70 fusion partners of the MLL gene have been characterized. 28 Deregulation of HOX seems to be one of the most important factors in MLL-induced leukemogenesis. Since HOX expression is high in stem cells and early precursors and needs to be downregulated for maturation, a continuous ectopic HOX expression will create a basis for the development of abnormal preleukemic precursors that may progress to various forms of acute leukemia. 28, 29 In cases 180 and 370 submitted to this session, the primary diagnosis was AML with t(9;11)(p22;q23), but the relapse presented as ALL/lymphoma with an EGIL B-I immunophenotype (CD10 negative). In the third patient (case 392), a therapyrelated myeloid neoplasm presented as a t(4;11)(q21;q23) B-ALL/lymphoma with an EGIL B-I immunophenotype, whereas AML with monocytic differentiation was seen at first relapse and B/myeloid MPAL at second relapse. The ❚Image 2❚ Flow cytometry immunophenotypic findings in case 208 (see Table 1 for details): Complicated case where it was difficult to differentiate CD45 low blasts from other leukocytes (upper row left plots). Granulocytes are intermingled with blasts, and there is also a continuum between lymphocytes and blasts. CD34 allows discriminating the myeloid blast population (upper row, right plots, CD34: dark blue dots, back-gated). CD34+ cells are CD19+ and express an unusual heterogeneous CD10 pattern (lower row, left plots). Myeloperoxidase expression is dim but definitively positive, and cytoplasmic CD79 is positive at a similar level as for normal B cells (lower row, right plots MLL-AF4 fusion has been reported in therapy-related ALL, after treatment with either topoisomerase II inhibitors or alkylating agents, and seems to be associated with a worse clinical outcome. 30, 31 What Are Some of the Important Technical and Interpretation Issues in the Diagnosis of MPAL?
MPO
The issue of MPO expression in the diagnosis of MPAL has been discussed in the literature. [32] [33] [34] Previous FrenchAmerican-British group guidelines, based on cytochemistry, used 3% of MPO-positive blasts in BM smears as sufficient to call a leukemia MPO positive. 35, 36 A threshold of 10% expression has been used by the EGIL group. 3 However, discordant cases are found when both methods are compared, 6, 37 leading to the conclusion that the 10% threshold may be conservative but not very sensitive. It should be emphasized that MPO expression can be a difficult test to establish by FCM immunophenotypic analysis since differences in permeabilization reagents and various antibodies have been reported. [38] [39] [40] Thus, MPO expression in leukemic blasts has to be compared with internal negative and positive controls. In a study comparing MPO expression detected by FCM and cytochemistry in cases of AML and ALL, a 13% threshold was found to be relevant using an isotype control as a background reference (sensitivity, 95.1%; specificity, 91.7%). 5 If residual normal lymphocytes were used as reference, a threshold of 28% had to be applied, yielding an improved 97.4% sensitivity and 96.1% specificity in distinguishing between ALL and AML. The WHO criteria for MPAL do not indicate any lower limit for MPO expression in leukemic blasts, 1 but it seems reasonable to use published thresholds. 3, 5 Since MPAL cases often show more than one population of blasts, MPO could be present in only a minor population, which has to be identified as the myeloid component. Another issue is that AML with minimal differentiation and no MPO expression could be involved in MPAL. Therefore, as stated in the WHO criteria, when there are two or more distinct populations of leukemic cells, one with coexpression of a number of myeloid markers, no MPO and no lymphoid markers also can be accepted to define the myeloid component of MPAL. 1 Rarely, cases of otherwise typical B-ALL/lymphoma can express MPO by FCM or IHC (case 259) or least often by cytochemistry. [32] [33] [34] 41 These cases are best classified and treated as B-ALL/lymphoma. In contrast, most MPAL cases show expression of other myeloid-associated markers and also are characterized by the presence of two or more subpopulations of blasts with slightly different immunophenotypes. In some cases of MPAL, MPO may be expressed only in a small subset of blasts, with or without lymphoid markers (biphenotypic or bilineal presentation).
Cytoplasmic CD3
Cytoplasmic CD3 (cCD3) is considered the most specific marker for the T-cell lineage and has been used to diagnose T-cell malignancies since the 1980s. 42, 43 FCM immunophenotyping methods to detect cCD3 were established in the 1990s when permeabilization reagents became available. 39, 40 As in the case of MPO, expression of cCD3 in leukemic blasts has to be determined in comparison with internal negative and positive controls (B cells, monocytes, granulocytes, and normal T lymphocytes, respectively). At least a fraction of blasts should express cCD3 at the level of A B normal T cells, and weak expression in a minor fraction of blasts is insufficient to diagnose MPAL. Many AML cases show aberrant expression of other T-cell-associated markers, such as CD2, CD4, CD5, or CD7, or NK-cell-associated markers, such as CD56. 44, 45 Thus, the correct interpretation of cCD3 staining is important for final diagnosis. If a BM biopsy specimen is available, the expression of cCD3 may be confirmed by IHC. In case 261, positive for CD2, CD4, and CD56, review of the FCM files revealed no sufficient cCD3 expression, and no confirmatory IHC could be performed. Thus, considering the presence of a complex karyotype, a consensus diagnosis of AML with myelodysplasia-related changes was rendered ❚Table 5❚. Similarly, in case 349 (Table 5) , expression of cCD3 was very weak and could not be confirmed by IHC. Also, in case 303 (Table 2) , heterogeneous expression of cCD3 was not confirmed by IHC, although a fraction of blasts that showed adequately high expression to qualify as MPAL was observed by FCM, together with CD5 and CD7. No cCD3 expression was seen at relapse in this patient.
CD19 and Other B-Cell Markers
The WHO classification provides no definite threshold for the size of the population expressing CD19 that is ❚Image 6❚ Immunohistochemistry on bone marrow biopsy sections of case 268 shows CD117+ PAX5-area (A, ×100) corresponding to acute myeloid leukemia and CD117-PAX5+ area (B, ×100) corresponding to mixed-phenotype acute leukemia B/T (see Image (Table 1) , criteria were met for the diagnosis of MPAL. The intensity of CD19 expression by blasts should be compared with that expected by normal B cells and, if comparable, considered bright. It has to be stressed that in cases in which the whole blast cell population strongly expresses CD19, with the immunophenotype otherwise being consistent with B-ALL/lymphoma, the presence of MPO expression as a sole aberrant marker should not dissuade therapy using a B-ALL regimen, and patient prognosis does not seem to differ from other patients with B-ALL. 32 
What Criteria Are Helpful in the Differential Diagnosis of AUL vs AML With Minimal Differentiation?
Five cases submitted to this session (cases 199, 250, 261, 349, and 396) illustrated classification difficulties between AUL and AML with minimal differentiation (Table  5 ). True AUL is very rare, and these neoplasms should not express markers of B, T, or myeloid lineage and should not fulfill criteria for B-or T-ALL, AML with minimal differentiation, or MPAL. Nevertheless, AUL cases can be positive for CD34, CD38, HLA-DR, and/or TdT. Importantly, there may be cases that cannot be adequately classified due to insufficient immunophenotyping data or discordant expression of various markers, rendering definitive classification impossible. The latter cases should be designated as acute 
